Skip to main content
Top
Published in: BioDrugs 1/2004

01-01-2004 | Novel Therapeutic Strategies

Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections

Authors: Mihai G. Netea, Bart-Jan Kullberg, Dr Jos W. M. Van der Meer

Published in: BioDrugs | Issue 1/2004

Login to get access

Abstract

Mortality due to severe bacterial infections has not been markedly effected by the introduction of new antimicrobial drugs over the last 30–40 years. This has emphasized the need for development of new therapeutic strategies to combat sepsis. The outcome of an infection depends on two factors: the growth of the microorganisms (including the effect of antibacterial drugs), and the host’s defensive response to the invading organism. It is known that injection of bacterial products into experimental animals leads to enhanced nonspecific resistance to a variety of microorganisms. The discovery of the specific mediators responsible for modulation of host defense has created new possibilities for the development of alternative treatment strategies. Molecules such as interleukins, interferons, tumor necrosis factors and hematopoietic growth factors have become available in recombinant form, and their therapeutic potential in various infectious diseases has been tested in various experimental models of infections. Initial data in various patient groups indicate that adjunctive therapy with recombinant proinflammatory cytokines may have beneficial effects in the treatment of bacterial and fungal infections.
Literature
1.
go back to reference Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227–42PubMed Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227–42PubMed
2.
go back to reference Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20: 143–58PubMedCrossRef Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20: 143–58PubMedCrossRef
3.
go back to reference Shilo M. Non-specific resistance to infection. Annu Rev Microbiol 1959; 13: 255–87CrossRef Shilo M. Non-specific resistance to infection. Annu Rev Microbiol 1959; 13: 255–87CrossRef
4.
go back to reference Dubos RJ, Schaedler RW. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections. J Exp Med 1957; 106: 703–17PubMedCrossRef Dubos RJ, Schaedler RW. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections. J Exp Med 1957; 106: 703–17PubMedCrossRef
5.
go back to reference Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869–71PubMedCrossRef Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869–71PubMedCrossRef
6.
go back to reference Tracey KJ, Fong Y, Hesse D, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4PubMedCrossRef Tracey KJ, Fong Y, Hesse D, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4PubMedCrossRef
7.
go back to reference Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxin shock by a tumor necrosis factor immunoadhesin. Proc Natl Acad Sci U S A 1991; 88: 10535–9PubMedCrossRef Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxin shock by a tumor necrosis factor immunoadhesin. Proc Natl Acad Sci U S A 1991; 88: 10535–9PubMedCrossRef
8.
go back to reference Wakabayashi G, Gelfand JA, Burke JF, et al. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338–43PubMed Wakabayashi G, Gelfand JA, Burke JF, et al. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338–43PubMed
9.
go back to reference Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–104PubMedCrossRef Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–104PubMedCrossRef
10.
go back to reference Wards A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099–100CrossRef Wards A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099–100CrossRef
11.
go back to reference Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314–25PubMed Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314–25PubMed
12.
go back to reference Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52PubMed Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52PubMed
13.
go back to reference Dinarello CA, Cannon JG, Wolff SM. New concepts on the pathogenesis of fever. Rev Infect Dis 1988; 10: 168–89PubMedCrossRef Dinarello CA, Cannon JG, Wolff SM. New concepts on the pathogenesis of fever. Rev Infect Dis 1988; 10: 168–89PubMedCrossRef
14.
go back to reference Van der Meer JW. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1988; 1: 19–25PubMedCrossRef Van der Meer JW. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1988; 1: 19–25PubMedCrossRef
15.
go back to reference Alexander HR, Doherty GM, Fraker DL, et al. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res 1991; 50: 421–4PubMedCrossRef Alexander HR, Doherty GM, Fraker DL, et al. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res 1991; 50: 421–4PubMedCrossRef
16.
go back to reference Van der Meer JW, Barza M, Wolff SM, et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci U S A 1988; 85: 1620–3PubMedCrossRef Van der Meer JW, Barza M, Wolff SM, et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci U S A 1988; 85: 1620–3PubMedCrossRef
17.
go back to reference Van’t Wout JW, Van der Meer JW, Barza M, et al. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18: 1143–6PubMedCrossRef Van’t Wout JW, Van der Meer JW, Barza M, et al. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18: 1143–6PubMedCrossRef
18.
go back to reference Dinarello CA, Krueger JM. Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. Fed Proc 1986; 45: 2545–8PubMed Dinarello CA, Krueger JM. Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. Fed Proc 1986; 45: 2545–8PubMed
19.
20.
go back to reference Chedid L, Parant M, Parant F, et al. Enhancement of nonspecific immunity to Klebsieila pneumoniae infection by a synthetic immunoadjuvant (Nacetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A 1977; 74: 2089–93PubMedCrossRef Chedid L, Parant M, Parant F, et al. Enhancement of nonspecific immunity to Klebsieila pneumoniae infection by a synthetic immunoadjuvant (Nacetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A 1977; 74: 2089–93PubMedCrossRef
21.
go back to reference Ozaki Y, Ohashi A, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1 alpha. Infect Immun 1987; 55: 1436–40PubMed Ozaki Y, Ohashi A, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1 alpha. Infect Immun 1987; 55: 1436–40PubMed
22.
go back to reference Minami A, Fujimoto K, Ozaki Y, et al. Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun 1988; 56: 3116–20PubMed Minami A, Fujimoto K, Ozaki Y, et al. Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun 1988; 56: 3116–20PubMed
23.
go back to reference Morikage T, Mizushima Y, Sakamoto K, et al. Prevention of fatal infections by recombinant human interleukin-1 alpha in normal and anticancer drug-treated mice. Cancer Res 1990; 50: 2099–104PubMed Morikage T, Mizushima Y, Sakamoto K, et al. Prevention of fatal infections by recombinant human interleukin-1 alpha in normal and anticancer drug-treated mice. Cancer Res 1990; 50: 2099–104PubMed
24.
go back to reference Campanile F, Binaglia L, Boraschi D, et al. Antibacterial resistance induced by recombinant interleukin-1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cell Immunol 1990; 128: 250–60PubMedCrossRef Campanile F, Binaglia L, Boraschi D, et al. Antibacterial resistance induced by recombinant interleukin-1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cell Immunol 1990; 128: 250–60PubMedCrossRef
25.
go back to reference Nakamura S, Minami A, Fujimoto K, et al. Combination effect of recombinant human interleukin-1 alpha with antimicrobial agents. Antimicrob Agents Chemother 1989; 33: 1804–10PubMedCrossRef Nakamura S, Minami A, Fujimoto K, et al. Combination effect of recombinant human interleukin-1 alpha with antimicrobial agents. Antimicrob Agents Chemother 1989; 33: 1804–10PubMedCrossRef
26.
go back to reference Amura CR, Fontan PA, Sanjuan N, et al. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin Immunol Immunopathol 1994; 73: 261–7PubMedCrossRef Amura CR, Fontan PA, Sanjuan N, et al. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin Immunol Immunopathol 1994; 73: 261–7PubMedCrossRef
27.
go back to reference Hochepied T, Van Molle W, Berger FG, et al. Involvement of the acute phase protein alpha1-acid glycoprotein in nonspecific resistance to a lethal Gramnegative infection. J Biol Chem 2000; 275: 14903–9PubMedCrossRef Hochepied T, Van Molle W, Berger FG, et al. Involvement of the acute phase protein alpha1-acid glycoprotein in nonspecific resistance to a lethal Gramnegative infection. J Biol Chem 2000; 275: 14903–9PubMedCrossRef
28.
go back to reference Mclntyre KW, Unowsky J, DeLorenzo W, et al. Enhancement of antibacterial resistance of neutropenic bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun 1989; 57: 48–54 Mclntyre KW, Unowsky J, DeLorenzo W, et al. Enhancement of antibacterial resistance of neutropenic bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun 1989; 57: 48–54
29.
go back to reference Kampschmidt RF, Pulliam LA. Stimulation of antimicrobial activity in the rat with leukocyte endogenous mediator. J Reticuloendothel Soc 1975; 17: 162–9PubMed Kampschmidt RF, Pulliam LA. Stimulation of antimicrobial activity in the rat with leukocyte endogenous mediator. J Reticuloendothel Soc 1975; 17: 162–9PubMed
30.
go back to reference Morrissey PJ, Charrier K. Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium. Infect Immun 1991; 59: 4729–31PubMed Morrissey PJ, Charrier K. Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium. Infect Immun 1991; 59: 4729–31PubMed
31.
go back to reference Morrissey PJ, Charrier K. Treatment of mice with IL-1 before infection increases resistance to a lethal challenge with Salmonella typhimurium: the effect correlates with the resistance allele at the Ity locus. J Immunol 1994; 153: 212–9PubMed Morrissey PJ, Charrier K. Treatment of mice with IL-1 before infection increases resistance to a lethal challenge with Salmonella typhimurium: the effect correlates with the resistance allele at the Ity locus. J Immunol 1994; 153: 212–9PubMed
32.
go back to reference Leshem B, Dekel R, Bercovier H, et al. Cytokine-induced resistance to microbial infections in normal, immunosuppressed and bone marrow transplanted mice. Bone Marrow Transpl 1992; 9: 471–7 Leshem B, Dekel R, Bercovier H, et al. Cytokine-induced resistance to microbial infections in normal, immunosuppressed and bone marrow transplanted mice. Bone Marrow Transpl 1992; 9: 471–7
33.
go back to reference Pelkonen S, Pluschke G. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microb Pathog 1989; 6: 415–24PubMedCrossRef Pelkonen S, Pluschke G. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microb Pathog 1989; 6: 415–24PubMedCrossRef
34.
go back to reference Lange JR, Alexander HR, Merino MJ, et al. Interleukin-1 alpha prevention of the lethality of Escherichia coli peritonitis. J Surg Res 1992; 52: 555–62PubMedCrossRef Lange JR, Alexander HR, Merino MJ, et al. Interleukin-1 alpha prevention of the lethality of Escherichia coli peritonitis. J Surg Res 1992; 52: 555–62PubMedCrossRef
35.
go back to reference Gladue R, Girard A, Newborg M. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents Actions 1988; 24: 130–6PubMedCrossRef Gladue R, Girard A, Newborg M. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents Actions 1988; 24: 130–6PubMedCrossRef
36.
go back to reference Hebert JC, O’Reilly M, Barry B, et al. Effects of exogenous cytokines on intravascular clearance of bacteria in normal and splenectomized mice. J Trauma 1997; 43: 875–82PubMedCrossRef Hebert JC, O’Reilly M, Barry B, et al. Effects of exogenous cytokines on intravascular clearance of bacteria in normal and splenectomized mice. J Trauma 1997; 43: 875–82PubMedCrossRef
37.
go back to reference Shi J, Goodband RD, Chengappa MM, et al. Influence of interleukin-1 on neutrophil function and resistance to Streptococcus suis in neonatal pigs. J Leukoc Biol 1994; 56: 88–94PubMed Shi J, Goodband RD, Chengappa MM, et al. Influence of interleukin-1 on neutrophil function and resistance to Streptococcus suis in neonatal pigs. J Leukoc Biol 1994; 56: 88–94PubMed
38.
go back to reference Liu Z, Simpson RJ, Cheers C. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection. Immunology 1995; 85: 562–7PubMed Liu Z, Simpson RJ, Cheers C. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection. Immunology 1995; 85: 562–7PubMed
39.
go back to reference Czuprynski CJ, Brown JF. Purified human and recombinant murine interleukin-1 induced accumulation of inflammatory peritoneal neutrophils and mononuclear phagocytes: possible contributions to antibacterial resistance. Microb Pathog 1987; 3: 377–86PubMedCrossRef Czuprynski CJ, Brown JF. Purified human and recombinant murine interleukin-1 induced accumulation of inflammatory peritoneal neutrophils and mononuclear phagocytes: possible contributions to antibacterial resistance. Microb Pathog 1987; 3: 377–86PubMedCrossRef
40.
go back to reference Czuprynski CJ, Brown JF. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun 1987; 55: 2061–5PubMed Czuprynski CJ, Brown JF. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun 1987; 55: 2061–5PubMed
41.
go back to reference Kurtz RS, Young KM, Czuprynski CJ. Separate and combined effects of recombinant interleukin-1 alpha and gamma interferon on antibacterial resistance. Infect Immun 1989; 57: 553–8PubMed Kurtz RS, Young KM, Czuprynski CJ. Separate and combined effects of recombinant interleukin-1 alpha and gamma interferon on antibacterial resistance. Infect Immun 1989; 57: 553–8PubMed
42.
go back to reference Kullberg BJ, Van’t Wout JW, van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319–24PubMed Kullberg BJ, Van’t Wout JW, van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319–24PubMed
43.
go back to reference Kullberg BJ, Van’t Wout JW, Poell RJ, et al. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in mice. Antimicrob Agents Chemother 1992; 36: 1225–9PubMedCrossRef Kullberg BJ, Van’t Wout JW, Poell RJ, et al. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in mice. Antimicrob Agents Chemother 1992; 36: 1225–9PubMedCrossRef
44.
go back to reference Van der Meer JW, Vogels MT, Kullberg BJ. Interleukin-1 and related proinflam-matory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 1994; 7: 161–7PubMedCrossRef Van der Meer JW, Vogels MT, Kullberg BJ. Interleukin-1 and related proinflam-matory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 1994; 7: 161–7PubMedCrossRef
45.
go back to reference Kullberg BJ, Vogels MT, Van der Meer JW. Immunomodulators in bacterial and fungal infections: a review of their therapeutic potential. Clin Immunother 1994; 1: 43–55CrossRef Kullberg BJ, Vogels MT, Van der Meer JW. Immunomodulators in bacterial and fungal infections: a review of their therapeutic potential. Clin Immunother 1994; 1: 43–55CrossRef
46.
go back to reference Porat R, Clark BD, Wolff SM, et al. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 1991; 254: 430–2PubMedCrossRef Porat R, Clark BD, Wolff SM, et al. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 1991; 254: 430–2PubMedCrossRef
47.
go back to reference Vogels MT, Hermsen CC, Huys HL, et al. Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun 1994; 62: 2065–70PubMed Vogels MT, Hermsen CC, Huys HL, et al. Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun 1994; 62: 2065–70PubMed
48.
go back to reference Vogels MT, Sweep CG, Hermus AR, et al. Interleukin-1-induced nonspecific resistance to bacterial infection in mice is not mediated by glucocorticosteroids. Antimicrob Agents Chemother 1992; 36: 2785–9PubMedCrossRef Vogels MT, Sweep CG, Hermus AR, et al. Interleukin-1-induced nonspecific resistance to bacterial infection in mice is not mediated by glucocorticosteroids. Antimicrob Agents Chemother 1992; 36: 2785–9PubMedCrossRef
49.
go back to reference Stork LC, Peterson VM, Rundus CH, et al. Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol 1988; 16: 163–7PubMed Stork LC, Peterson VM, Rundus CH, et al. Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol 1988; 16: 163–7PubMed
50.
go back to reference Fibbe WE, Van der Meer JW, Falkenburg JH, et al. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol 1989; 17: 805–8PubMed Fibbe WE, Van der Meer JW, Falkenburg JH, et al. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol 1989; 17: 805–8PubMed
51.
go back to reference Rogers HW, Tripp CS, Schreiber RD, et al. Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994; 153: 2093–101PubMed Rogers HW, Tripp CS, Schreiber RD, et al. Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994; 153: 2093–101PubMed
52.
go back to reference Kullberg BJ, Van’t Wout JW, van Furth R. No effect of recombinant human interleukin-1 on numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991; 15: 457–70PubMedCrossRef Kullberg BJ, Van’t Wout JW, van Furth R. No effect of recombinant human interleukin-1 on numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991; 15: 457–70PubMedCrossRef
53.
go back to reference Georgilis K, Schaefer C, Dinarello CA, et al. Human recombinant interleukin 1 beta has no effect on intracellular calcium or on functional responses of human neutrophils. J Immunol 1987; 138: 3403–7PubMed Georgilis K, Schaefer C, Dinarello CA, et al. Human recombinant interleukin 1 beta has no effect on intracellular calcium or on functional responses of human neutrophils. J Immunol 1987; 138: 3403–7PubMed
54.
go back to reference Vogels MT, Van Rooyen N, Bemelmans MHA, et al. Interleukin-1 (IL-l)-induced resistance to bacterial infection: role of macrophage and soluble TNF receptors. In: Mechanisms of enhanced natural resistance to infection induced by interleukin-1. Nijmegen: Catholic Unversity Nijmegen, 1994: 117–34 Vogels MT, Van Rooyen N, Bemelmans MHA, et al. Interleukin-1 (IL-l)-induced resistance to bacterial infection: role of macrophage and soluble TNF receptors. In: Mechanisms of enhanced natural resistance to infection induced by interleukin-1. Nijmegen: Catholic Unversity Nijmegen, 1994: 117–34
55.
go back to reference Langermans JA, Van der Hulst ME, Nibbering PH, et al. IFN-gamma-induced Larginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor alpha. J Immunol 1992; 148: 568–74PubMed Langermans JA, Van der Hulst ME, Nibbering PH, et al. IFN-gamma-induced Larginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor alpha. J Immunol 1992; 148: 568–74PubMed
56.
go back to reference Cheers C, Zhan YF, Egan PJ. In vivo IL-1 potentiates both specific and nonspecific arms of immune reponse to infection. Immunology 1990; 70: 411–3PubMed Cheers C, Zhan YF, Egan PJ. In vivo IL-1 potentiates both specific and nonspecific arms of immune reponse to infection. Immunology 1990; 70: 411–3PubMed
57.
go back to reference Hunter CA, Chizzonite R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. J Immunol 1995; 155: 4347–54PubMed Hunter CA, Chizzonite R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. J Immunol 1995; 155: 4347–54PubMed
58.
go back to reference Vogels MTE, Cantoni L, Carelli M, et al. Role of acute phase proteins in interleukin-1-induced resistance to bacterial infection in mice. Antimicrob Agents Chemother 1993; 37: 2527–33PubMedCrossRef Vogels MTE, Cantoni L, Carelli M, et al. Role of acute phase proteins in interleukin-1-induced resistance to bacterial infection in mice. Antimicrob Agents Chemother 1993; 37: 2527–33PubMedCrossRef
59.
go back to reference Van der Meer JW, Helle M, Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 in nonspecific resistance to infection. Eur J Immunol 1989; 19: 413–6PubMedCrossRef Van der Meer JW, Helle M, Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 in nonspecific resistance to infection. Eur J Immunol 1989; 19: 413–6PubMedCrossRef
60.
go back to reference Vogels MT, Lindley IJ, Curfs JH, et al. Effects of interleukin-8 on non-specific resistance to infection in neutropenic and normal mice. Antimicrob Agents Chemother 1993; 37: 276–80PubMedCrossRef Vogels MT, Lindley IJ, Curfs JH, et al. Effects of interleukin-8 on non-specific resistance to infection in neutropenic and normal mice. Antimicrob Agents Chemother 1993; 37: 276–80PubMedCrossRef
61.
go back to reference Vogels MT, Mensink EJ, Ye K, et al. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol 1994; 153: 5772–80PubMed Vogels MT, Mensink EJ, Ye K, et al. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol 1994; 153: 5772–80PubMed
62.
go back to reference Holtmann H, Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin-1 and 4beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139: 1161–7PubMed Holtmann H, Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin-1 and 4beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139: 1161–7PubMed
63.
go back to reference Beekhuizen H, Corsel-Van Tilburg AJ, Blokland I, et al. Characterization of the adherence of human monocytes to cytokine-stimulated human macrovascular endothelial cells. Immunology 1991; 74: 661–9PubMed Beekhuizen H, Corsel-Van Tilburg AJ, Blokland I, et al. Characterization of the adherence of human monocytes to cytokine-stimulated human macrovascular endothelial cells. Immunology 1991; 74: 661–9PubMed
64.
go back to reference Ulich TR, del Castillo J, Keys M, et al. Kinetics and mechanisms of recombinant human interleukin-1 and tumor necrosis factor alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139: 3406–15PubMed Ulich TR, del Castillo J, Keys M, et al. Kinetics and mechanisms of recombinant human interleukin-1 and tumor necrosis factor alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139: 3406–15PubMed
65.
go back to reference Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte macrophage colony-stimulating factor. J Immunol 1988; 140: 108–11PubMed Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte macrophage colony-stimulating factor. J Immunol 1988; 140: 108–11PubMed
66.
go back to reference White CW, Ghezzi P. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1989; 1: 361–7PubMedCrossRef White CW, Ghezzi P. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1989; 1: 361–7PubMedCrossRef
67.
go back to reference Brown J, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A 1990; 87: 5026–30PubMedCrossRef Brown J, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A 1990; 87: 5026–30PubMedCrossRef
68.
go back to reference Puri RK, Travis WD, Rosenberg SA. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 1989; 49: 969–76PubMed Puri RK, Travis WD, Rosenberg SA. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 1989; 49: 969–76PubMed
70.
go back to reference Mancuso G, Tomasello F, Migliardo M, et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994; 62: 4997–5003PubMed Mancuso G, Tomasello F, Migliardo M, et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994; 62: 4997–5003PubMed
71.
go back to reference Barton BE, Shortall J, Jackson JV. Interleukin-6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64: 714–20PubMed Barton BE, Shortall J, Jackson JV. Interleukin-6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64: 714–20PubMed
72.
73.
go back to reference Vasalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411–43CrossRef Vasalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411–43CrossRef
74.
go back to reference Beutler B, Krochin N, Milsark IW, et al. Control of cachexin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977–80PubMedCrossRef Beutler B, Krochin N, Milsark IW, et al. Control of cachexin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977–80PubMedCrossRef
75.
go back to reference Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–4PubMedCrossRef Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–4PubMedCrossRef
76.
go back to reference Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28–31PubMedCrossRef Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28–31PubMedCrossRef
77.
go back to reference van der Poll T, Lowry SF. Tumor necrosis factor and sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3: 1–12PubMed van der Poll T, Lowry SF. Tumor necrosis factor and sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3: 1–12PubMed
78.
go back to reference Fischer Jr CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318–27CrossRef Fischer Jr CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318–27CrossRef
79.
go back to reference Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995; 273: 934–41PubMedCrossRef Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995; 273: 934–41PubMedCrossRef
80.
go back to reference Fischer CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor: Fc fusion protein. N Engl J Med 1996; 334: 1697–702CrossRef Fischer CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor: Fc fusion protein. N Engl J Med 1996; 334: 1697–702CrossRef
81.
go back to reference Figari IS, Mori NA, Palladino Jr MA. Regulation of neutrophil migration and Superoxide production by recombinant tumor necrosis factors-alpha and -beta: comparison to recombinant interferon-gamma and interleukin-1 alpha. Blood 1987; 70: 979–84PubMed Figari IS, Mori NA, Palladino Jr MA. Regulation of neutrophil migration and Superoxide production by recombinant tumor necrosis factors-alpha and -beta: comparison to recombinant interferon-gamma and interleukin-1 alpha. Blood 1987; 70: 979–84PubMed
82.
go back to reference Seow WK, Thong YH, Ferrante A. Macrophage-neutrophil interactions: contrasting effects of the monokines interleukin-1 and tumour necrosis factor (cachectin) on human neutrophil adherence. Immunology 1987; 62: 357–61PubMed Seow WK, Thong YH, Ferrante A. Macrophage-neutrophil interactions: contrasting effects of the monokines interleukin-1 and tumour necrosis factor (cachectin) on human neutrophil adherence. Immunology 1987; 62: 357–61PubMed
83.
go back to reference Steinbeck MA, Roth JA. Neutrophil activation by recombinant cytokines. Rev Infect Dis 1989; 11: 549–68PubMedCrossRef Steinbeck MA, Roth JA. Neutrophil activation by recombinant cytokines. Rev Infect Dis 1989; 11: 549–68PubMedCrossRef
84.
go back to reference Nacy CA, Meierovics AI, Belosevic M, et al. Tumor necrosis factor alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 1991; 59: 182–4PubMedCrossRef Nacy CA, Meierovics AI, Belosevic M, et al. Tumor necrosis factor alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 1991; 59: 182–4PubMedCrossRef
85.
go back to reference Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 263–9 Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 263–9
86.
go back to reference Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731–40PubMedCrossRef Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731–40PubMedCrossRef
87.
go back to reference Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762–6PubMed Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762–6PubMed
88.
go back to reference Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003–8PubMed Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003–8PubMed
89.
go back to reference Netea MG, van Tits LJ, Curfs JH, et al. Increased susceptibility of TNF-alpha lymphotoxin alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 1999; 163(3): 1498–505PubMed Netea MG, van Tits LJ, Curfs JH, et al. Increased susceptibility of TNF-alpha lymphotoxin alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 1999; 163(3): 1498–505PubMed
90.
go back to reference Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression. Arthritis Rheum 2003; 48: 1853–7PubMedCrossRef Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression. Arthritis Rheum 2003; 48: 1853–7PubMedCrossRef
91.
go back to reference Chen GH, Reddy RC, Newstead MW, et al. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165: 6496–503PubMed Chen GH, Reddy RC, Newstead MW, et al. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165: 6496–503PubMed
92.
go back to reference Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor alpha protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J Clin Invest 1991; 88: 34–9PubMedCrossRef Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor alpha protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J Clin Invest 1991; 88: 34–9PubMedCrossRef
93.
go back to reference Cross AS, Sadoff JC, Kelly N, et al. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine recombinant interleukin-1 alpha protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021–7PubMedCrossRef Cross AS, Sadoff JC, Kelly N, et al. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine recombinant interleukin-1 alpha protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021–7PubMedCrossRef
94.
go back to reference Parant F, Tavernier J, Fiers W, et al. Comparative activity of human and murine tumor necrosis factor in toxicity and anti-infectious assays in mice. Microb Pathog 1990; 8: 143–9PubMedCrossRef Parant F, Tavernier J, Fiers W, et al. Comparative activity of human and murine tumor necrosis factor in toxicity and anti-infectious assays in mice. Microb Pathog 1990; 8: 143–9PubMedCrossRef
95.
go back to reference Nauciel C, Espinasse-Maes F. Role of gamma-interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450–4PubMed Nauciel C, Espinasse-Maes F. Role of gamma-interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450–4PubMed
96.
go back to reference Nakano Y, Onozuka K, Terada Y, et al. Protective effect of recombinant tumor necrosis factor alpha in murine salmonellosis. J Immunol 1990; 144: 1935–41PubMed Nakano Y, Onozuka K, Terada Y, et al. Protective effect of recombinant tumor necrosis factor alpha in murine salmonellosis. J Immunol 1990; 144: 1935–41PubMed
97.
go back to reference Morrissey PJ, Charrier K, Vogel SN. Exogenous tumor necrosis factor alpha and interleukin-1 alpha increase resistance to Salmonella typhimurium: efficacy is influenced by the Ity and Lps loci. Infect Immun 1995; 63: 3196–201PubMed Morrissey PJ, Charrier K, Vogel SN. Exogenous tumor necrosis factor alpha and interleukin-1 alpha increase resistance to Salmonella typhimurium: efficacy is influenced by the Ity and Lps loci. Infect Immun 1995; 63: 3196–201PubMed
98.
go back to reference Blanchard DK, Djeu JY, Klein TW, et al. Protective effect of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol 1988; 43: 429–35PubMed Blanchard DK, Djeu JY, Klein TW, et al. Protective effect of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol 1988; 43: 429–35PubMed
99.
go back to reference Vaudaux P, Grau GE, Huggler E, et al. Contribution of tumor necrosis factor to host defense against staphylococci in a guinea pig model of foreign body infections. J Infect Dis 1992; 166: 58–64PubMedCrossRef Vaudaux P, Grau GE, Huggler E, et al. Contribution of tumor necrosis factor to host defense against staphylococci in a guinea pig model of foreign body infections. J Infect Dis 1992; 166: 58–64PubMedCrossRef
100.
go back to reference Nordmann P, Ronco E, Guenounou M. Involvement of interferon-gamma and tumor necrosis factor alpha in host defense against Rhodococcus equi. J Infect Dis 1993; 166: 58–64 Nordmann P, Ronco E, Guenounou M. Involvement of interferon-gamma and tumor necrosis factor alpha in host defense against Rhodococcus equi. J Infect Dis 1993; 166: 58–64
101.
go back to reference Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol 1987; 139: 4225–31PubMed Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol 1987; 139: 4225–31PubMed
102.
go back to reference Desiderio JV, Kiener PA, Lin FP, et al. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor. Infect Immun 1989; 57: 1615–7PubMed Desiderio JV, Kiener PA, Lin FP, et al. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor. Infect Immun 1989; 57: 1615–7PubMed
103.
go back to reference Roll JT, Young KM, Kurtz RS, et al. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology 1990; 69: 316–22PubMed Roll JT, Young KM, Kurtz RS, et al. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology 1990; 69: 316–22PubMed
104.
go back to reference van Furth R, van Zwet TL, Buisman AM, et al. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994; 170: 234–7PubMedCrossRef van Furth R, van Zwet TL, Buisman AM, et al. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994; 170: 234–7PubMedCrossRef
105.
go back to reference Sarmento AM, Appelberg R. Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor alpha production in infected mice and in in-vitro mouse macrophages. Infect Immun 1995; 63: 3759–65PubMed Sarmento AM, Appelberg R. Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor alpha production in infected mice and in in-vitro mouse macrophages. Infect Immun 1995; 63: 3759–65PubMed
106.
go back to reference Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140: 3006–13PubMed Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140: 3006–13PubMed
107.
go back to reference Bermudez LE, Stevens P, Kolonoski P, et al. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 1989; 143: 2996–3000PubMed Bermudez LE, Stevens P, Kolonoski P, et al. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 1989; 143: 2996–3000PubMed
108.
go back to reference Williams DM, Magee DM, Bonewald LF, et al. A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun 1990; 58: 1572–6PubMed Williams DM, Magee DM, Bonewald LF, et al. A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun 1990; 58: 1572–6PubMed
109.
go back to reference Nagai H, Guo J, Choi H, et al. Interferon-gamma and tumor necrosis factor alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554–60PubMedCrossRef Nagai H, Guo J, Choi H, et al. Interferon-gamma and tumor necrosis factor alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554–60PubMedCrossRef
110.
go back to reference Nakane A, Minagawa T, Kohanawa M, et al. Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance and primary and secondary Listeria monocytogenes infections. Infect Immun 1989; 57: 3331–7PubMed Nakane A, Minagawa T, Kohanawa M, et al. Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance and primary and secondary Listeria monocytogenes infections. Infect Immun 1989; 57: 3331–7PubMed
111.
go back to reference Djeu JY, Blanchard DK, Halkias D, et al. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol 1986; 137: 2980–4PubMed Djeu JY, Blanchard DK, Halkias D, et al. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol 1986; 137: 2980–4PubMed
112.
go back to reference Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115–22PubMed Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115–22PubMed
113.
go back to reference Sypek JP, Jacobson S, Vorys A, et al. Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages. Infect Immun 1993; 61: 3901–6PubMed Sypek JP, Jacobson S, Vorys A, et al. Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages. Infect Immun 1993; 61: 3901–6PubMed
114.
go back to reference Mastroeni P, Skepper JN, Hormaeche CE. Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections. Infect Immun 1995; 63: 3674–82PubMed Mastroeni P, Skepper JN, Hormaeche CE. Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections. Infect Immun 1995; 63: 3674–82PubMed
115.
go back to reference Vasquez-Torres A, Fantuzzi G, Edwards CK, et al. Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A 2001; 98: 2561–5CrossRef Vasquez-Torres A, Fantuzzi G, Edwards CK, et al. Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A 2001; 98: 2561–5CrossRef
116.
go back to reference Wong GHW, Elwell JH, Oberley LH, et al. Manganous Superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989; 58: 923–30PubMedCrossRef Wong GHW, Elwell JH, Oberley LH, et al. Manganous Superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989; 58: 923–30PubMedCrossRef
117.
go back to reference Dinarello CA, Cannon JG, Wolff SM. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163: 1433–50PubMedCrossRef Dinarello CA, Cannon JG, Wolff SM. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163: 1433–50PubMedCrossRef
118.
go back to reference Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A 1993; 90: 3725–9PubMedCrossRef Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A 1993; 90: 3725–9PubMedCrossRef
119.
go back to reference Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–85PubMedCrossRef Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–85PubMedCrossRef
120.
go back to reference Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988; 167: 1511–6PubMedCrossRef Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988; 167: 1511–6PubMedCrossRef
121.
go back to reference Wheelock EF. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310–1CrossRef Wheelock EF. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310–1CrossRef
122.
123.
go back to reference Greenlund AC, Schreiber RD, Goeddel DV, et al. Interferon-gamma induces receptor dimerization in solution and on cells. J Biol Chem 1993; 268: 18103–12PubMed Greenlund AC, Schreiber RD, Goeddel DV, et al. Interferon-gamma induces receptor dimerization in solution and on cells. J Biol Chem 1993; 268: 18103–12PubMed
124.
go back to reference Klebanoff SJ, Olszowski S, van Voorhis WC, et al. Effect of gamma-interferon on human neutrophils: protection from deterioration from storage. Blood 1992; 80: 225–33PubMed Klebanoff SJ, Olszowski S, van Voorhis WC, et al. Effect of gamma-interferon on human neutrophils: protection from deterioration from storage. Blood 1992; 80: 225–33PubMed
125.
go back to reference Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97: 459–67PubMedCrossRef Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97: 459–67PubMedCrossRef
126.
go back to reference Gallin JI, Farber JM, Holland SM, et al. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123: 216–22PubMed Gallin JI, Farber JM, Holland SM, et al. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123: 216–22PubMed
127.
go back to reference Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739–42PubMedCrossRef Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739–42PubMedCrossRef
128.
go back to reference Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259: 1742–5PubMedCrossRef Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259: 1742–5PubMedCrossRef
129.
go back to reference Kamijo R, Le J, Shapiro D, et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178:1435–40PubMedCrossRef Kamijo R, Le J, Shapiro D, et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178:1435–40PubMedCrossRef
130.
go back to reference Buchmeier NA, Schreiber RD. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A 1985; 82: 7404–8PubMedCrossRef Buchmeier NA, Schreiber RD. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A 1985; 82: 7404–8PubMedCrossRef
131.
go back to reference Langermans JA, Mayanski DM, Nibbering PH, et al. Effect of IFN-gamma and endogenous TNF on the histopathological changes in the liver of Listeria monocytogenes-infected mice. Immunology 1994; 81: 192–7PubMed Langermans JA, Mayanski DM, Nibbering PH, et al. Effect of IFN-gamma and endogenous TNF on the histopathological changes in the liver of Listeria monocytogenes-infected mice. Immunology 1994; 81: 192–7PubMed
132.
go back to reference Kiderlen A, Kauffmann HE, Lohmann-Matthes ML. Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur J Immunol 1984; 14: 964–7PubMedCrossRef Kiderlen A, Kauffmann HE, Lohmann-Matthes ML. Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur J Immunol 1984; 14: 964–7PubMedCrossRef
133.
go back to reference Langermans JA, van der Hulst ME, Nibbering PH, et al. Intravenous injection of IFN-gamma inhibits the proliferation of Listeria monocytogenes in the liver but not in the spleen and peritoneal cavity. Immunology 1992; 77: 354–61PubMed Langermans JA, van der Hulst ME, Nibbering PH, et al. Intravenous injection of IFN-gamma inhibits the proliferation of Listeria monocytogenes in the liver but not in the spleen and peritoneal cavity. Immunology 1992; 77: 354–61PubMed
134.
go back to reference Portnoy DA, Schreiber RD, Connelly P, et al. Gamma-interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med 1989; 170: 2141–6PubMedCrossRef Portnoy DA, Schreiber RD, Connelly P, et al. Gamma-interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med 1989; 170: 2141–6PubMedCrossRef
135.
go back to reference Tripp CS, Kanagawa O, Unanue ER. Secondary response to Listeria infection requires interferon-gamma but is partially independent of IL-12. J Immunol 1995; 155: 3427–33PubMed Tripp CS, Kanagawa O, Unanue ER. Secondary response to Listeria infection requires interferon-gamma but is partially independent of IL-12. J Immunol 1995; 155: 3427–33PubMed
136.
go back to reference Muotiala A, Makela PH. The role of IFN-gamma in murine Salmonella typhimurium infection. Microb Pathog 1990; 8: 135–41PubMedCrossRef Muotiala A, Makela PH. The role of IFN-gamma in murine Salmonella typhimurium infection. Microb Pathog 1990; 8: 135–41PubMedCrossRef
137.
go back to reference Edwards III CK, Hedegard HB, Zlotnik A. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol 1986; 136: 1820–7PubMed Edwards III CK, Hedegard HB, Zlotnik A. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol 1986; 136: 1820–7PubMed
138.
go back to reference Khor M, Lowrie DB, Coates AR, et al. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol 1986; 67: 587–96PubMed Khor M, Lowrie DB, Coates AR, et al. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol 1986; 67: 587–96PubMed
139.
go back to reference Klein TW, Yamamoto Y, Brown HK, et al. Interferon-gamma induced resistance to Legionella pneumophila in susceptible A/J mouse macrophages. J Leukocyte Biol 1991; 49: 98–103PubMed Klein TW, Yamamoto Y, Brown HK, et al. Interferon-gamma induced resistance to Legionella pneumophila in susceptible A/J mouse macrophages. J Leukocyte Biol 1991; 49: 98–103PubMed
140.
go back to reference Skerrett SJ, Martin TR. Intratracheal interferon-gamma augments pulmonary defense in experimental legionellosis. Am J Respir Crit Care Med 1994; 149: 50–8PubMed Skerrett SJ, Martin TR. Intratracheal interferon-gamma augments pulmonary defense in experimental legionellosis. Am J Respir Crit Care Med 1994; 149: 50–8PubMed
141.
go back to reference Canning PC, Roth JA. Effects of in vitro and in vivo administration of recombinant bovine interferon-gamma on bovine neutrophil responses to Bruceila abortus. Vet Immunol Immunopathol 1989; 20: 119–33PubMedCrossRef Canning PC, Roth JA. Effects of in vitro and in vivo administration of recombinant bovine interferon-gamma on bovine neutrophil responses to Bruceila abortus. Vet Immunol Immunopathol 1989; 20: 119–33PubMedCrossRef
142.
go back to reference Bohn E, Heesemann J, Ehlers S, et al. Early gamma interferon mRNA expression is associated with resistance of mice against Yersinia enterocolitica. Infect Immun 1994; 62: 3027–33PubMed Bohn E, Heesemann J, Ehlers S, et al. Early gamma interferon mRNA expression is associated with resistance of mice against Yersinia enterocolitica. Infect Immun 1994; 62: 3027–33PubMed
143.
go back to reference Johansen HK, Hougen HP, Rygaard J, et al. Interferon-gamma treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996; 103: 212–8PubMedCrossRef Johansen HK, Hougen HP, Rygaard J, et al. Interferon-gamma treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996; 103: 212–8PubMedCrossRef
144.
go back to reference Hershman MJ, Polk HC, Pietsch JD, et al. Modulation of infection by gamma interferon treatment following trauma. Infect Immun 1988; 56: 2412–8PubMed Hershman MJ, Polk HC, Pietsch JD, et al. Modulation of infection by gamma interferon treatment following trauma. Infect Immun 1988; 56: 2412–8PubMed
145.
go back to reference ten Hagen TL, van Vianen W, Bakker-Woudenberg IA. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J Infect Dis 1995; 171(2): 385–92PubMedCrossRef ten Hagen TL, van Vianen W, Bakker-Woudenberg IA. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J Infect Dis 1995; 171(2): 385–92PubMedCrossRef
146.
go back to reference Hershman MJ, Sonnenfeld G, Logan WA, et al. Effect of interferon-gamma treatment on the course of a burn wound infection. J Interferon Res 1988; 8: 367–72PubMedCrossRef Hershman MJ, Sonnenfeld G, Logan WA, et al. Effect of interferon-gamma treatment on the course of a burn wound infection. J Interferon Res 1988; 8: 367–72PubMedCrossRef
147.
go back to reference Rozalska B, Wadstrom T. Interferon-gamma, interleukin-1, and tumor necrosis factor alpha synthesis during experimental murine staphylococcal infection. FEMS Microbiol Immunol 1993; 7: 145–53 Rozalska B, Wadstrom T. Interferon-gamma, interleukin-1, and tumor necrosis factor alpha synthesis during experimental murine staphylococcal infection. FEMS Microbiol Immunol 1993; 7: 145–53
148.
go back to reference Boelens JJ, van der Poll T, Dankert J, et al. Interferon-gamma protects against biomaterial-associated Staphylococcus epidermidis infection in mice. J Infect Dis 2000; 181: 1167–71PubMedCrossRef Boelens JJ, van der Poll T, Dankert J, et al. Interferon-gamma protects against biomaterial-associated Staphylococcus epidermidis infection in mice. J Infect Dis 2000; 181: 1167–71PubMedCrossRef
149.
go back to reference Byrne GI, Grubbs B, Marshall TJ, et al. Gamma interferon-mediated cytotoxity related to murine Chlamydia trachomatis infection. Infect Immun 1988; 56: 2023–7PubMed Byrne GI, Grubbs B, Marshall TJ, et al. Gamma interferon-mediated cytotoxity related to murine Chlamydia trachomatis infection. Infect Immun 1988; 56: 2023–7PubMed
150.
go back to reference Kullberg BJ, Van’t Wout JW, Hoogstraten C, et al. Recombinant interferongamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436–43PubMedCrossRef Kullberg BJ, Van’t Wout JW, Hoogstraten C, et al. Recombinant interferongamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436–43PubMedCrossRef
151.
go back to reference Joly V, Saint-Julien L, Carbon C, et al. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170: 1331–4PubMedCrossRef Joly V, Saint-Julien L, Carbon C, et al. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170: 1331–4PubMedCrossRef
152.
go back to reference Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46: 437–42PubMedCrossRef Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46: 437–42PubMedCrossRef
153.
go back to reference Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491–4CrossRef Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491–4CrossRef
154.
go back to reference Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol 2001; 38: 903–9CrossRef Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol 2001; 38: 903–9CrossRef
155.
go back to reference Hsieh CS, Macatonia SE, Tripp CS, et al. Development of Thl CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547–9PubMedCrossRef Hsieh CS, Macatonia SE, Tripp CS, et al. Development of Thl CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547–9PubMedCrossRef
156.
go back to reference Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of TNF-alpha. J Immunol 1990; 145: 4290–7PubMed Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of TNF-alpha. J Immunol 1990; 145: 4290–7PubMed
157.
go back to reference Agarwall BB, Eesallu TE, Hass PE. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665–8CrossRef Agarwall BB, Eesallu TE, Hass PE. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665–8CrossRef
158.
go back to reference Geertsma MF, Nibbering PH, Pos O, et al. Interferon-gamma-activated human granulocytes kill ingested Mycobacterium fortuitum more efficiently than normal granulocytes. Eur J Immunol 1990; 20: 869–73PubMedCrossRef Geertsma MF, Nibbering PH, Pos O, et al. Interferon-gamma-activated human granulocytes kill ingested Mycobacterium fortuitum more efficiently than normal granulocytes. Eur J Immunol 1990; 20: 869–73PubMedCrossRef
159.
go back to reference Gallin JI. Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 1991; 13: 973–8PubMedCrossRef Gallin JI. Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 1991; 13: 973–8PubMedCrossRef
160.
go back to reference Gallin JI, Malech HL, Melnick DA, et al. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509–16CrossRef Gallin JI, Malech HL, Melnick DA, et al. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509–16CrossRef
161.
go back to reference Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease: European follow-up study. Eur J Pediatr 1995; 154: 295–302PubMed Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease: European follow-up study. Eur J Pediatr 1995; 154: 295–302PubMed
162.
go back to reference Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 1985; 134: 1619–22PubMed Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 1985; 134: 1619–22PubMed
163.
go back to reference Jendrossek V, Peters AMJ, Buth S, et al. Improvement of Superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood 1993; 81: 2131–7PubMed Jendrossek V, Peters AMJ, Buth S, et al. Improvement of Superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood 1993; 81: 2131–7PubMed
164.
go back to reference Muhlebach TJ, Gabay J, Nathan CF, et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. Clin Exp Immunol 1992; 88(2): 203–10PubMedCrossRef Muhlebach TJ, Gabay J, Nathan CF, et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. Clin Exp Immunol 1992; 88(2): 203–10PubMedCrossRef
165.
go back to reference Ezekowitz RAB, Dinauer MC, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146–51PubMedCrossRef Ezekowitz RAB, Dinauer MC, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146–51PubMedCrossRef
166.
go back to reference Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849–52PubMedCrossRef Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849–52PubMedCrossRef
167.
go back to reference Weisbart RH, Kwan L, Golde DW, et al. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to major physiological chemoattractants. Blood 1987; 69: 18–21PubMed Weisbart RH, Kwan L, Golde DW, et al. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to major physiological chemoattractants. Blood 1987; 69: 18–21PubMed
168.
go back to reference Nathan CF, Kaplan G, Lewis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–12PubMedCrossRef Nathan CF, Kaplan G, Lewis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–12PubMedCrossRef
169.
go back to reference Kaplan G, Mathur NK, Job CK, et al. Effect of multiple interferon-gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 1989; 86: 8073–7PubMedCrossRef Kaplan G, Mathur NK, Job CK, et al. Effect of multiple interferon-gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 1989; 86: 8073–7PubMedCrossRef
170.
go back to reference Samuel NM, Grange JM, Samule S, et al. A study of the effects of intradermal administration of recombinant interferon-gamma in lepromatous leprosy patients. Lepr Rev 1987; 58: 389–96PubMed Samuel NM, Grange JM, Samule S, et al. A study of the effects of intradermal administration of recombinant interferon-gamma in lepromatous leprosy patients. Lepr Rev 1987; 58: 389–96PubMed
171.
go back to reference Damasco MH, Sarno EN, Lobao AS, et al. Effect of cutaneous cell-mediated immune response to rIFN gamma on Mycobacterium leprae viability in the lesions of lepromatous leprosy. Braz J Med Biol Res 1992; 25: 457–63PubMed Damasco MH, Sarno EN, Lobao AS, et al. Effect of cutaneous cell-mediated immune response to rIFN gamma on Mycobacterium leprae viability in the lesions of lepromatous leprosy. Braz J Med Biol Res 1992; 25: 457–63PubMed
172.
go back to reference Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348–52PubMedCrossRef Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348–52PubMedCrossRef
173.
go back to reference Chatte G, Panteix G, Perrin-Fayolle M, et al. Aerosolized interfeon-gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995; 152: 1094–101PubMed Chatte G, Panteix G, Perrin-Fayolle M, et al. Aerosolized interfeon-gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995; 152: 1094–101PubMed
174.
go back to reference Squires KE, Murphy WF, Madoff LC, et al. Interferon-gamma and Mycobacterium avium-intracellular infection. J Infect Dis 1989; 159: 599–607PubMedCrossRef Squires KE, Murphy WF, Madoff LC, et al. Interferon-gamma and Mycobacterium avium-intracellular infection. J Infect Dis 1989; 159: 599–607PubMedCrossRef
175.
go back to reference Bermudez LE, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother 1991; 35: 2625–30PubMedCrossRef Bermudez LE, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother 1991; 35: 2625–30PubMedCrossRef
176.
go back to reference Dries DJ, Jurkovich GJ, Maie RV, et al. Effect of interferon gamma on infectionrelated death in patients with severe injuries. Arch Surg 1994; 129: 1031–41PubMedCrossRef Dries DJ, Jurkovich GJ, Maie RV, et al. Effect of interferon gamma on infectionrelated death in patients with severe injuries. Arch Surg 1994; 129: 1031–41PubMedCrossRef
177.
go back to reference Poynton CH, Barnes RA, Rees J. Interferon-gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239–40PubMedCrossRef Poynton CH, Barnes RA, Rees J. Interferon-gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239–40PubMedCrossRef
178.
go back to reference Riddell LA, Pinching AJ, Hill S, et al. A phase II study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17: 789–97PubMedCrossRef Riddell LA, Pinching AJ, Hill S, et al. A phase II study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17: 789–97PubMedCrossRef
179.
go back to reference Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 1995; 21: 1439–49PubMedCrossRef Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 1995; 21: 1439–49PubMedCrossRef
180.
go back to reference Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827–35PubMedCrossRef Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827–35PubMedCrossRef
181.
go back to reference Cassatella MA, Meda L, Gasperini S, et al. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995; 25: 1–7PubMedCrossRef Cassatella MA, Meda L, Gasperini S, et al. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995; 25: 1–7PubMedCrossRef
182.
go back to reference Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251–76PubMedCrossRef Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251–76PubMedCrossRef
183.
go back to reference D’Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulating factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387–94PubMedCrossRef D’Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulating factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387–94PubMedCrossRef
184.
go back to reference Ma Y, Seiler KP, Tai K-F, et al. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62: 3663–8PubMed Ma Y, Seiler KP, Tai K-F, et al. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62: 3663–8PubMed
185.
go back to reference Sieling PA, Wang X-H, Gately MK, et al. IL-12 regulates T helper cytokine responses in human infectious disease. J Immunol 1994; 153: 3639–46PubMed Sieling PA, Wang X-H, Gately MK, et al. IL-12 regulates T helper cytokine responses in human infectious disease. J Immunol 1994; 153: 3639–46PubMed
186.
go back to reference Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733–9PubMedCrossRef Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733–9PubMedCrossRef
187.
go back to reference Romani L, Bistoni F, Mencacci A, et al. IL-12 in Candida albicans infections. Res Immunol 1995; 146: 532–8PubMedCrossRef Romani L, Bistoni F, Mencacci A, et al. IL-12 in Candida albicans infections. Res Immunol 1995; 146: 532–8PubMedCrossRef
188.
189.
go back to reference Greenberger MJ, Kunkel SL, Strieter RM, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996; 157: 3006–12PubMed Greenberger MJ, Kunkel SL, Strieter RM, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996; 157: 3006–12PubMed
190.
go back to reference Jiang C, Magee DM, Cox RA. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental cocidioidomycosis. Infect Immun 1999; 67: 2996–3001PubMed Jiang C, Magee DM, Cox RA. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental cocidioidomycosis. Infect Immun 1999; 67: 2996–3001PubMed
191.
go back to reference Wagner RD, Steinberg H, Brown JF, et al. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994; 17: 175–7PubMedCrossRef Wagner RD, Steinberg H, Brown JF, et al. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994; 17: 175–7PubMedCrossRef
192.
go back to reference Gladue PR, Laquerre AM, Magna HA, et al. In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats. Cytokine 1994; 6: 318–23PubMedCrossRef Gladue PR, Laquerre AM, Magna HA, et al. In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats. Cytokine 1994; 6: 318–23PubMedCrossRef
193.
go back to reference Tripp CS, Gately MK, Hakimi J, et al. Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice: reversal by IFN-gamma. J Immunol 1994; 152: 1883–90PubMed Tripp CS, Gately MK, Hakimi J, et al. Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice: reversal by IFN-gamma. J Immunol 1994; 152: 1883–90PubMed
194.
go back to reference Flynn JL, Goldstein MM, Triebold KJ, et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2515–22PubMed Flynn JL, Goldstein MM, Triebold KJ, et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2515–22PubMed
195.
go back to reference Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cell Immunol 1994; 156: 529–36PubMedCrossRef Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cell Immunol 1994; 156: 529–36PubMedCrossRef
196.
go back to reference Kobayashi K, Kasama T, Yamazaki J, et al. Protection of mice from Mycobacterium avium infection by recombinant interleukin-12. Antimicrob Agents Chemother 1995; 39: 1369–71PubMedCrossRef Kobayashi K, Kasama T, Yamazaki J, et al. Protection of mice from Mycobacterium avium infection by recombinant interleukin-12. Antimicrob Agents Chemother 1995; 39: 1369–71PubMedCrossRef
197.
go back to reference Kobayashi K, Yamazaki J, Kasama T, et al. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy. J Infect Dis 1996; 174: 564–73PubMedCrossRef Kobayashi K, Yamazaki J, Kasama T, et al. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy. J Infect Dis 1996; 174: 564–73PubMedCrossRef
198.
go back to reference Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995; 63: 4099–104PubMed Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995; 63: 4099–104PubMed
199.
go back to reference Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995; 63: 4011–5PubMed Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995; 63: 4011–5PubMed
200.
go back to reference Castro AG, Silva RA, Appelberg R. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995; 155: 2013–9PubMed Castro AG, Silva RA, Appelberg R. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995; 155: 2013–9PubMed
201.
go back to reference Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428–35PubMed Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428–35PubMed
202.
go back to reference Metzger DW, Raeder R, Van Cleave VH, et al. Protection of mice from group A streptococcal skin infection by interleukin-12. J Infect Dis 1995; 171: 1643–5PubMedCrossRef Metzger DW, Raeder R, Van Cleave VH, et al. Protection of mice from group A streptococcal skin infection by interleukin-12. J Infect Dis 1995; 171: 1643–5PubMedCrossRef
203.
go back to reference Mastroeni P, Harrison JA, Chabalgoity JA, et al. Effect of interleukin-12 neutralization on host resistance and interferon gamma production in mouse typhoid. Infect Immun 1996; 64: 189–95PubMed Mastroeni P, Harrison JA, Chabalgoity JA, et al. Effect of interleukin-12 neutralization on host resistance and interferon gamma production in mouse typhoid. Infect Immun 1996; 64: 189–95PubMed
204.
go back to reference Bohn E, Autenrieth IB. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ cells. J Immunol 1996; 156: 1458–64PubMed Bohn E, Autenrieth IB. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ cells. J Immunol 1996; 156: 1458–64PubMed
205.
go back to reference Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun 1995; 63: 1387–90PubMed Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun 1995; 63: 1387–90PubMed
206.
go back to reference Huang J, Wang M-D, Lenz S, et al. IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J Immunol 1999; 162: 2217–26PubMed Huang J, Wang M-D, Lenz S, et al. IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J Immunol 1999; 162: 2217–26PubMed
207.
go back to reference Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38: 460–4PubMedCrossRef Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38: 460–4PubMedCrossRef
208.
go back to reference Romani L, Mencacci A, Tonnetti L, et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 153: 5167–75PubMed Romani L, Mencacci A, Tonnetti L, et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 153: 5167–75PubMed
209.
go back to reference Romani L, Mencaci A, Cenci E, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158: 5349–56PubMed Romani L, Mencaci A, Cenci E, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158: 5349–56PubMed
210.
go back to reference Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leuk Biol 1998; 63: 658–64 Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leuk Biol 1998; 63: 658–64
211.
go back to reference Ye K, Clark BD, Dinarello CA. Interleukin-1 downregulates gene and surface expression of interleukin-1 receptor type 1 by destabilizing its mRNA, whereas interleukin-2 increases its expression. Immunology 1992; 75: 427–34PubMed Ye K, Clark BD, Dinarello CA. Interleukin-1 downregulates gene and surface expression of interleukin-1 receptor type 1 by destabilizing its mRNA, whereas interleukin-2 increases its expression. Immunology 1992; 75: 427–34PubMed
212.
go back to reference Flesch IEA, Hess JH, Huang S, et al. Early interleukin-12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181: 1615–23PubMedCrossRef Flesch IEA, Hess JH, Huang S, et al. Early interleukin-12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181: 1615–23PubMedCrossRef
213.
go back to reference Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400–7PubMed Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400–7PubMed
214.
go back to reference Chehimi J, Tarr SE, Frank I, et al. Natural killer (NK) cells stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789–95PubMedCrossRef Chehimi J, Tarr SE, Frank I, et al. Natural killer (NK) cells stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789–95PubMedCrossRef
215.
go back to reference Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94: 2435–42PubMedCrossRef Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94: 2435–42PubMedCrossRef
216.
go back to reference Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFNgamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999; 104: 761–7PubMedCrossRef Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFNgamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999; 104: 761–7PubMedCrossRef
217.
go back to reference Novick D, Kim S-H, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127–36PubMedCrossRef Novick D, Kim S-H, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127–36PubMedCrossRef
218.
go back to reference Netea MG, Fantuzzi G, Kullberg BJ, et al. Neutralization of interleukin-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000; 164: 2644–9PubMed Netea MG, Fantuzzi G, Kullberg BJ, et al. Neutralization of interleukin-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000; 164: 2644–9PubMed
219.
go back to reference Puren AJ, Fantuzzi G, Gu Y, et al. Interleukin-18 (IFNgamma inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD 14+ human mononuclear cells. J Clin Invest 1998; 101: 711–21PubMedCrossRef Puren AJ, Fantuzzi G, Gu Y, et al. Interleukin-18 (IFNgamma inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD 14+ human mononuclear cells. J Clin Invest 1998; 101: 711–21PubMedCrossRef
220.
go back to reference Sugawara I, Yamada H, Kaneko H, et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67: 2585–9PubMed Sugawara I, Yamada H, Kaneko H, et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67: 2585–9PubMed
221.
go back to reference Kinjo Y, Kawakami K, Uezu K, et al. Contribution of IL-18 to Thl response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12 p40. J Immunol 2002; 169: 323–9PubMed Kinjo Y, Kawakami K, Uezu K, et al. Contribution of IL-18 to Thl response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12 p40. J Immunol 2002; 169: 323–9PubMed
222.
go back to reference Bohn E, Sing A, Zumbihl R, et al. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160: 299–307PubMed Bohn E, Sing A, Zumbihl R, et al. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160: 299–307PubMed
223.
go back to reference Wei X-Q, Leung BP, Niedbala W, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163: 2821–8PubMed Wei X-Q, Leung BP, Niedbala W, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163: 2821–8PubMed
224.
go back to reference Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial response to pneumococcal pneumonia. J Immunol 2002; 168: 372–8PubMed Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial response to pneumococcal pneumonia. J Immunol 2002; 168: 372–8PubMed
225.
go back to reference Huang X, McClellan SA, Barrett RP, et al. IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFNgamma production. J Immunol 2002; 168: 5756–63PubMed Huang X, McClellan SA, Barrett RP, et al. IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFNgamma production. J Immunol 2002; 168: 5756–63PubMed
226.
go back to reference Neighbors M, Xu X, Barrat FJ, et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon-gamma production. J Exp Med 2001; 194: 343–54PubMedCrossRef Neighbors M, Xu X, Barrat FJ, et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon-gamma production. J Exp Med 2001; 194: 343–54PubMedCrossRef
227.
go back to reference Mastroeni P, Clare S, Khan S, et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun 1999; 67: 478–83PubMed Mastroeni P, Clare S, Khan S, et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun 1999; 67: 478–83PubMed
228.
go back to reference Kawakami K, Koguchi Y, Qureshi MH, et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186: 121–6PubMedCrossRef Kawakami K, Koguchi Y, Qureshi MH, et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186: 121–6PubMedCrossRef
229.
go back to reference Stuyt RJ, Netea MG, Verschueren I, et al. Role of interleukin-18 in host defense against disseminated Candida albicans infection. Infect Immun 2002; 70: 3284–6PubMedCrossRef Stuyt RJ, Netea MG, Verschueren I, et al. Role of interleukin-18 in host defense against disseminated Candida albicans infection. Infect Immun 2002; 70: 3284–6PubMedCrossRef
230.
go back to reference Kawakami K, Qureshi MH, Zhang T, et al. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFNgamma production. J Immunol 1997; 159: 5528–34PubMed Kawakami K, Qureshi MH, Zhang T, et al. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFNgamma production. J Immunol 1997; 159: 5528–34PubMed
231.
go back to reference Mencacci A, Bacci A, Cenci E, et al. Interleukin 18 restores defective Thl immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000; 68: 5126–31PubMedCrossRef Mencacci A, Bacci A, Cenci E, et al. Interleukin 18 restores defective Thl immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000; 68: 5126–31PubMedCrossRef
232.
go back to reference Ohkusu K, Yoshimoto T, Takeda K, et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68: 2449–56PubMedCrossRef Ohkusu K, Yoshimoto T, Takeda K, et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68: 2449–56PubMedCrossRef
233.
go back to reference Cai G, Kastelein R, Hunter CA. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000; 68: 6932–8PubMedCrossRef Cai G, Kastelein R, Hunter CA. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000; 68: 6932–8PubMedCrossRef
234.
go back to reference Kim SH, Cho D, Kim TS. Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology 2001; 102: 234–41PubMedCrossRef Kim SH, Cho D, Kim TS. Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology 2001; 102: 234–41PubMedCrossRef
235.
go back to reference Zhang T, Kawakami K, Qureshi MH, et al. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun 1997; 65: 3594–9PubMed Zhang T, Kawakami K, Qureshi MH, et al. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun 1997; 65: 3594–9PubMed
236.
go back to reference Kawakami K, Qureshi MH, Koguchi Y, et al. Role of TNF in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18. Cell Immunol 1999; 193: 9–16PubMedCrossRef Kawakami K, Qureshi MH, Koguchi Y, et al. Role of TNF in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18. Cell Immunol 1999; 193: 9–16PubMedCrossRef
237.
go back to reference Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907–13PubMed Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907–13PubMed
238.
go back to reference Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756–61PubMedCrossRef Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756–61PubMedCrossRef
239.
go back to reference Debs RJ, Fuchs HJ, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990; 50: 375–80PubMed Debs RJ, Fuchs HJ, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990; 50: 375–80PubMed
240.
go back to reference Mullerad J, Cohen S, Voronov E, et al. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin-1 via biodegradable microspheres. Cytokine 2000; 12: 1683–90PubMedCrossRef Mullerad J, Cohen S, Voronov E, et al. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin-1 via biodegradable microspheres. Cytokine 2000; 12: 1683–90PubMedCrossRef
241.
go back to reference ten Hagen TL, van Vianen W, Savelkoul HF, et al. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidyethanolamine or gamma interferon. Infect Immun 1998; 66(5): 1962–7PubMed ten Hagen TL, van Vianen W, Savelkoul HF, et al. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidyethanolamine or gamma interferon. Infect Immun 1998; 66(5): 1962–7PubMed
Metadata
Title
Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections
Authors
Mihai G. Netea
Bart-Jan Kullberg
Dr Jos W. M. Van der Meer
Publication date
01-01-2004
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 1/2004
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200418010-00002

Other articles of this Issue 1/2004

BioDrugs 1/2004 Go to the issue